Lilly Says Volume Growth Strategy, Launches Working Despite Price Pressures

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Trulicity, Taltz grew in the first quarter, but below analyst consensus estimates. Company points to price decreases as holding down growth.

Indianapolis - Circa April 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals IV
Lilly posted 7% volume growth during the first quarter, but that was offset by pricing pressures

Eli Lilly & Co. painted a bright picture of its strategy to grow via business volume and product launches on 30 April but first quarter sales growth for a pair of those newer products, Taltz and Trulicity, fell below analyst consensus estimates. The Indianapolis pharma told its first quarter 2019 earnings call that pricing pressures are constraining growth but insisted that its overall strategy is delivering.

Lilly said worldwide pharmaceutical revenue grew by 3% year-over-year to nearly $5.1bn. Prescription volume increased by 7% during the quarter...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Nancy Tests SPARC-1036

Nancy tests Jira ticket SPARC-1036: Make anchor link work on initial page load

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.